Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison May 01, 2023 1:34pm
138 Views
Post# 35423196

RE:RE:Theralase AUA Pesentation at annual meeting

RE:RE:Theralase AUA Pesentation at annual meetingHi Legit62,  I will strongly repeat the remarks I made about the clinicians meeting which also applies to this AUA presentation and that is there are very few people that attend these meetings that are retail stock buyers.  If anything they invest into is done through their financial advisors and probably mutual funds or hedge funds. A person attending in todays medical environment is swamped with patients,  these people don't have the time or desire to be spending hours looking up data. I do think a few will be impressed enough by Theralase to make a call to their financial advisor to buy into this stock but it won't be until they get back home or after they see the next set of numbers.

What will really move this stock is the news media and more buy ratings from Financial Institutions, all this in my opinion could happen with our expectations of BTD, AA and advancements in partnerships and yes GBM,  NSCLC or moves in Covid-19 vaccine/therapeutics. 
<< Previous
Bullboard Posts
Next >>